GH Research PLC GHRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $10.50
- Day Range
- $10.40–10.96
- 52-Week Range
- $5.05–14.64
- Bid/Ask
- $10.51 / $11.17
- Market Cap
- $546.82 Mil
- Volume/Avg
- 19,952 / 126,389
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.ghres.com
Comparables
Valuation
Metric
|
GHRS
|
PRTA
|
ZURA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.50 | 1.97 | 2.66 |
Price/Sales | — | 11.97 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GHRS
PRTA
ZURA
Financial Strength
Metric
|
GHRS
|
PRTA
|
ZURA
|
---|---|---|---|
Quick Ratio | 24.14 | 10.97 | 4.92 |
Current Ratio | 24.49 | 11.24 | 4.97 |
Interest Coverage | −706.38 | — | — |
Quick Ratio
GHRS
PRTA
ZURA
Profitability
Metric
|
GHRS
|
PRTA
|
ZURA
|
---|---|---|---|
Return on Assets (Normalized) | −12.75% | −14.95% | −71.08% |
Return on Equity (Normalized) | −13.12% | −18.32% | −139.85% |
Return on Invested Capital (Normalized) | −16.87% | −22.78% | −99.89% |
Return on Assets
GHRS
PRTA
ZURA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mjjnhxggg | Fxmr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zhcysfsf | Rhznxn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rldqlfdf | Jczbql | $97.8 Bil | |
MRNA
| Moderna Inc | Xfvsnnv | Rvykd | $41.3 Bil | |
ARGX
| argenx SE ADR | Gfhldxj | Tbmc | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Dyscgwrr | Ykfz | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rdgpjzfg | Bxjzbzt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rdcrxwxyy | Mkjjwk | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wlvsnxvdhx | Wldfghj | $12.5 Bil | |
INCY
| Incyte Corp | Jwvfjkdv | Jnffjs | $11.6 Bil |